[8-K] Korro Bio, Inc. Reports Material Event

Rhea-AI Filing Summary

Korro Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to a Form 8-K and included a Cover Page Interactive Data file as Exhibit 104. The Form 8-K states the press release is being furnished and expressly notes that the information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.

The 8-K itself contains no financial figures or tables; readers must review Exhibit 99.1 for the company’s reported results. The report also confirms Korro’s common stock trades under the symbol KRRO on The Nasdaq Capital Market.

Insights

Financial Analyst

TL;DR: Routine 8-K furnishing a press release; the filing contains no financial details itself.

The company furnished a press release reporting quarter-end results (June 30, 2025) as Exhibit 99.1 and included an Inline XBRL cover page file as Exhibit 104. The filing explicitly states the exhibit is "furnished" and not "filed," limiting Section 18 liability. Because no revenue, profit, cash, or guidance figures appear in the 8-K text, the document on its own provides no new quantitative information for valuation or short-term trading decisions.

Corporate Governance Expert

TL;DR: Procedural disclosure that preserves legal distinctions between furnished and filed materials.

The Form 8-K follows standard disclosure practice by furnishing the press release and noting legal treatment of the exhibit. The filing includes the company’s registered trading symbol KRRO and identifies the press release as Exhibit 99.1 and the interactive data file as Exhibit 104. No governance or management changes, material transactions, or risk disclosures are presented in this filing.

0001703647falseNASDAQ00017036472025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39062	47-2324450
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
60 First Street, 2nd floor, Suite 250 Cambridge, MA		02141
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 468-1999

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		KRRO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2025, Korro Bio, Inc., or Korro, issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Korro Bio, Inc., dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KORRO BIO, INC.
Date: August 12, 2025	By:	/s/ Ram Aiyar
		Name: Ram Aiyar
		Title: President and Chief Executive Officer